GLP1R and diabetes mellitus: The introduction of sodium–glucose co-transporter-2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP-1 RAs) has revolutionized diabetes care, offering consistent cardiovascular and renal benefits [3,4,5,6,7].